



Pamela Munster

Professor of Medicine (Oncology)

Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Oncology**

875 Blake Wilbur Dr

MC 6560

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 724-3556

Bio

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor-Univ Med Line, Medicine - Oncology

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (1999)
- Fellowship: Memorial Sloan Kettering Cancer Center (1999) NY
- Residency: Indiana University School of Medicine (1996) IN
- Medical Education: Berne University School of Medicine (1989) Switzerland
- MD, University of Bern, Switzerland , Medicine (1989)

Publications

PUBLICATIONS

- **Cracks in the Estrogen Carcinogenesis of Breast Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Kim, J., Munster, P. N.
2026; 44 (18): 1660-1664
- **Combined PARP inhibition and immune checkpoint blockade elicit differentially improved survival in BRCA1, BRCA2 vs CHEK2, ATM deficient breast cancer by promoting an anti-tumor immune response through tertiary lymphoid structure formation**
Chaudhuri, S., Emata, A., Thomas, S., Munster, P. N.
AMER ASSOC CANCER RESEARCH.2026: 6557
- **Sequencing full-length mRNA in whole blood of breast cancer patients for antibody-drug conjugate therapy selection**
Bradley, J., Benitez, G., Barnett, M., Eve, O., Ivanova, I., Morris, K., Seguret, A., Zyoude, A., Davey, J., Cheng, Y., Robinson, A., Turnbull, A., Dixon, et al
AMER ASSOC CANCER RESEARCH.2026

- **The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial** *CLINICAL CANCER RESEARCH*
Schram, A. M., Naqash, A., Haura, E. B., Riess, J. W., Ulahannan, S. V., Ou, S. I., Munster, P. N., Cheng, M. L., Gustafson, W., Bitman, B., Friedman, R., Penn, R., Kar, et al
2025; 31 (23): 4933-4943
- **Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer** *NPJ BREAST CANCER*
Huppert, L. A., Gliwa, A. S., Tait, M., Quintal, L., Starzinski, S., Cheung, A., Moasser, M., Majure, M., Melisko, M., Munster, P., Rugo, H. S., Campbell, M., Fong, et al
2025; 11 (1): 130
- **Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma** *JOURNAL OF CLINICAL ONCOLOGY*
Zandberg, D. P., Allred, J. B., Rosenberg, A. J., Kaczmar, J. M., Swiecicki, P., Julian, R. A., Poklepovic, A. S., Bauman, J. R., Phan, M. D., Saba, N. F., Rivera, E., Rowland, K., Davar, et al
2025; 43 (21): 2398-2408
- **A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).**
Zandberg, D., Allred, J. B., Rosenberg, A., Kaczmar, J. M., Swiecicki, P., Julian, R., Poklepovic, A., Bauman, J. R., Phan, M., Saba, N. F., Ellerton, J., Ohr, J., Cordes, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: 6002
- **Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator's choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.**
Van Tine, B., Allred, J. B., Hensley, M., Arend, R., Charlson, J. A., D'Amato, G. Z., Lee, T., Loggers, E., Berg, S. A., Ingham, M., Mandrekar, S. J., Munster, P. N., Schwartz, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: 11507
- **A phase I/Ib study of olaparib and ASTX727 in BRCA 1/2-and HRD-mutated tumors**
Munster, P. N., Kelley, R., Calabrese, S., Walker, K., Clark, E., Lam, P., Berkley, S., Thomas, S., Monga, V.
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS3183
- **Estrogens and breast cancer** *ANNALS OF ONCOLOGY*
Kim, J., Munster, P. N.
2025; 36 (2): 134-148
- **Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant** *SCIENTIFIC REPORTS*
Thomas, S., Roche, E., Desai, P., Pawlowska, N., Bauer, D., Gingrich, D., Hsu, E., Deitchman, A. N., Aweeka, F., Munster, P. N.
2025; 15 (1): 3028
- **Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors** *BREAST CANCER RESEARCH*
Pacaud, R., Thomas, S., Chaudhuri, S., Lazar, A., Timmerman, L. A., Munster, P. N.
2025; 27 (1): 8
- **Phase II Study of Isatuximab, and Weekly Carfilzomib plus Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)**
Vesole, D. H., Martin, T. G., Trudel, S., Schade, H., Shenoy, S., Biran, N., Wolf, J., Matous, J., Munster, P., Berkeley, S., Berdeja, J. G.
ELSEVIER.2024: 1983
- **Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies** *JCO PRECISION ONCOLOGY*
Tsang, E. S., Aggarwal, R. R., Bergsland, E. K., Calabrese, S., Rozie, A., Chaudhuri, S., Dhawan, M. S., Pawlowska, N., Grabowsky, J., Thomas, S., Munster, P. N.
2024; 8: e2400328
- **A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies**
Rosen, L. S., Azad, N., Costa, R., Meric-Bernstam, F., Alaoui, H., Jablons, D. M., Munster, P., Hamilton, E. P.
ELSEVIER.2024: S531

- **ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.** *Cancer research communications*
Chen, C. T., Khanna, V., Kummar, S., Abdul-Karim, R. M., Sommerhalder, D., Tolcher, A. W., Ueno, N. T., Davis, S. L., Orr, D. W., Hamilton, E., Patel, M. R., Spira, A. I., Jauhari, et al
2024
- **A Phase II Trial of the WEE1 Inhibitor Adavosertib in *SETD2*-Altered Advanced Solid Tumor Malignancies (NCI 10170)** *CANCER RESEARCH COMMUNICATIONS*
Maldonado, E., Rathmell, W., Shapiro, G. I., Takebe, N., Rodon, J., Mahalingam, D., Trikalinos, N. A., Kalebast, A. R., Parikh, M., Boerner, S. A., Balido, C., Krings, G., Burns, et al
2024; 4 (7): 1793-1801
- **BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2-breast cancer (BC)**
Juric, D., Patel, M. R., Duska, L. R., Jhaveri, K. L., Henick, B. S., Matulonis, U. A., Munster, P. N., Birrer, M. J., Moore, K. N., Curigliano, G., Li, C., Guo, J., He, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with *MAPK* pathway alterations: A ComboMATCH treatment trial**
Shergill, A., Liao, C., Elsaid, M. I., Al Baghdadi, T., Ji, Y., Feldman, D., George, S., O'Reilly, E. M., Meyerhardt, J. A., Berg, S. A., Schwartz, G. K., Munster, P. N., Bekaii-Saab, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPAR α , as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors** *CANCER RESEARCH COMMUNICATIONS*
Yarchoan, M., Powderly, J. D., Bastos, B. R., Karasic, T. B., Crysler, O. V., Munster, P. N., McKean, M. A., Emens, L. A., Saenger, Y. M., Ged, Y., Stagg, R., Smith, S., Whiting, et al
2024; 4 (4): 1100-1110
- **First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy** *EUROPEAN UROLOGY ONCOLOGY*
Nguyen, H. G., van den Berg, N. S., Antaris, A. L., Xue, L., Greenberg, S., Rosenthal, J., Muchnik, A., Klaassen, A., Simko, J. P., Dutta, S., Sorger, J. M., Munster, P., Carroll, et al
2024; 7 (1): 63-72
- **Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies** *CLINICAL CANCER RESEARCH*
Carneiro, B. A., Cavalcante, L., Mahalingam, D., Saeed, A., Safran, H., Ma, W., Covelev, A. L., Powell, S., Bastos, B., Davis, E., Sahai, V., Mikrut, W., Longstreth, et al
2024; 30 (3): 522-531
- **Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study** *CANCER RESEARCH COMMUNICATIONS*
Munster, P., Iannotti, N., Cho, D. C., Kirkwood, J. M., Villaruz, L. C., Gibney, G. T., Hodi, F., Mettu, N. B., Jones, M., Bowman, J., Smith, M., Lakshminarayanan, M., O'Day, et al
2023; 3 (12): 2572-2584
- **Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study**
Xu, R., Xu, Y., Yan, D., Munster, P., Ruan, D., Deng, Y., Pan, H., Underhill, C. R., Richardson, G., Nordman, I., Lee, K., Wei, S., Li, et al
ELSEVIER.2023: S410-S411
- **Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).**
Huppert, L., Gliwa, A. S., Tait, M., Quintal, L., Starzinski, S., Cheung, A., Moasser, M. M., Majure, M., Melisko, M. E., Rugo, H. S., Munster, P. N., Campbell, M. J., Fong, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas** *BRITISH JOURNAL OF CANCER*

- Raj, N., Chan, J. A., Wang, S. J., Aggarwal, R. R., Calabrese, S., DeMore, A., Fong, L., Grabowsky, J., Hope, T. A., Kolli, K., Mulvey, C. K., Munster, P. N., Perez, et al
2023; 129 (2): 291-300
- **ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER plus /human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study**
Hurvitz, S. A., Schott, A. F., Ma, C., Hamilton, E. P., Nanda, R., Zahrah, G., Hunter, N., Tan, A. R., Telli, M. L., Mesias, J. A., Jeselsohn, R., Munster, P., Lu, et al
CHURCHILL LIVINGSTONE.2023: S116
 - **Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Ho, A. L., Foster, N. R., Zoroufy, A. J., Campbell, J. D., Worden, F., Price, K., Adkins, D., Bowles, D. W., Kang, H., Burtress, B., Sherman, E., Morton, R., Morris, et al
2022; 40 (36): 4240-4249
 - **Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors** *CLINICAL CANCER RESEARCH*
Munster, P. N., Greenstein, A. E., Fleming, G. F., Borazanci, E., Sharma, M. R., Custodio, J. M., Tudor, I., Pashova, H. I., Shepherd, S., Grauer, A., Sachdev, J. C.
2022; 28 (15): 3214-3224
 - **Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.**
Lynch, R. C., Munster, P. N., Advani, R. H., Hamadani, M., Spigel, D. R., Falchook, G., Patel, M. R., Siegel, D., Beri, N., Nowakowski, G. S., Palmisiano, N., Burness, M., Moore, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
 - **Updated survival follow-up for phase I study of abexinostat with pazopanib in patients with solid tumor malignancies.**
Tsang, E. S., Aggarwal, R., Thomas, S., Dhawan, M., Pawlowska, N., Bartelink, I., Grabowsky, J. A., Jahan, T., Truong, T., Ryan, C. J., Munster, P. N.
LIPPINCOTT WILLIAMS & WILKINS.2022
 - **First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation**
Dumbrava, E., Johnson, M., Tolcher, A. W., Shapiro, G., Thompson, J. A., El-Khoueiry, A. B., Vandross, A., Kummar, S., Parikh, A., Munster, P. N., Daly, E., De Leon, L., Khaddar, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
 - **MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3.) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY REFRACTORY**
Odia, Y., Cavalcante, L., Safran, H., Powell, S., Munster, P., Ma, W., Carneiro, B., Bastos, B., Giles, F., Sahebjam, S.
OXFORD UNIV PRESS INC.2021: 61-62
 - **Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies**
Aggarwal, R., Umetsu, S., Dhawan, M., Grabowsky, J., Carnevale, J., Howell, M., Wilch, L., Chapman, J., Alvarez, E., Calabrese, S., Smith, S., Shah, N., Dean, et al
ELSEVIER.2021: S583
 - **A Phase 1 Dose-Escalation and Expansion Study of Telaglenastat in Patients With Advanced or Metastatic Solid Tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Harding, J. J., Telli, M., Munster, P., Voss, M. H., Infante, J. R., DeMichele, A., Dunphy, M., Le, M. H., Molineaux, C., Orford, K., Parlati, F., Whiting, S. H., Bennett, et al
2021
 - **Specialized computational methods for denoising, B₂ correction, and kinetic modeling in hyperpolarized ¹³C MR EPSI studies of liver tumors** *MAGNETIC RESONANCE IN MEDICINE*
Lee, P. M., Chen, H., Gordon, J. W., Zhu, Z., Larson, P. E. Z., Dwork, N., Van Criekinge, M., Carvajal, L., Ohliger, M. A., Wang, Z. J., Xu, D., Kurhanewicz, J., Bok, et al
2021; 86 (5): 2402-2411
 - **First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.**

Lynch, R. C., Bendell, J. C., Advani, R. H., Falchook, G., Munster, P. N., Patel, M. R., Gutierrez, M., Burness, M., Palmisiano, N., Hamadani, M., Bradley, W. D., O'Shea, T. J., Doleman, et al
LIPPINCOTT WILLIAMS & WILKINS.2021

- **A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101 ORAL ONCOLOGY**
Jelinek, M. J., Foster, N. R., Zoroufy, A. J., Schwartz, G. K., Munster, P. N., Seiwert, T. Y., de Souza, J. A., Vokes, E. E.
2021; 114: 105171
- **Inhibition of MET Signaling with Ficlatusumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. *Blood cancer discovery***
Wang, V. E., Blaser, B. W., Patel, R. K., Behbehani, G. K., Rao, A. A., Durbin-Johnson, B., Jiang, T., Logan, A. C., Settles, M., Mannis, G. N., Olin, R., Damon, L. E., Martin, et al
2021; 2 (5): 434-449
- **Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer *NATURE COMMUNICATIONS***
Terranova-Barberio, M., Pawlowska, N., Dhawan, M., Moasser, M., Chien, A. J., Melisko, M. E., Rugo, H., Rahimi, R., Deal, T., Daud, A., Rosenblum, M. D., Thomas, S., Munster, et al
2020; 11 (1): 3584
- **A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. *PloS one***
Wolin, E., Mita, A., Mahipal, A., Meyer, T., Bendell, J., Nemunaitis, J., Munster, P. N., Paz-Ares, L., Filvaroff, E. H., Li, S., Hege, K., de Haan, H., Mita, et al
2019; 14 (9): e0221994
- **A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma *PIGMENT CELL & MELANOMA RESEARCH***
Algazi, A., Rotow, J., Posch, C., Ortiz-Urda, S., Algazi, A., Munster, P. N., Daud, A.
2019; 32 (4): 603-606
- **The PHACT Study: Population Health and Cancer Testing**
Dhawan, M., Karipineni, S., Budge, J., Mak, J., Zhou, A., Williams, K., Cha, K., Munster, P. N.
AMER SOC CLINICAL ONCOLOGY.2019
- **Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.**
Aggarwal, R., Thomas, S., Pawlowska, N., Grabowsky, J. A., Calabrese, S., Phu Lam, Comerford, K., Bautista, D., Munster, P. N.
AMER SOC CLINICAL ONCOLOGY.2019
- **Maintenance Lenalidomide in Primary CNS Lymphoma. *Annals of oncology : official journal of the European Society for Medical Oncology***
Rubenstein, J. L., Geng, H., Vu, K., Mannis, G., Formaker, P., Hwang, J., Munster, P. N., Damato, B.
2019
- **Coil combination methods for multi-channel hyperpolarized ¹³C imaging data from human studies *JOURNAL OF MAGNETIC RESONANCE***
Zhu, Z., Zhu, X., Ohliger, M. A., Tang, S., Cao, P., Carvajal, L., Autry, A. W., Li, Y., Kurhanewicz, J., Chang, S., Aggarwal, R., Munster, P., Xu, et al
2019; 301: 73-79
- **CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.**
Meric-Bernstam, F., Lee, R. J., Carthon, B., Iliopoulos, O., Mier, J., Patel, M. R., Tannir, N. M., Owonikoko, T., Haas, N. B., Voss, M., Harding, J. J., Srinivasan, R., Shapiro, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. *Oncology***
Hong, D. n., Rasco, D. n., Veeder, M. n., Luke, J. J., Chandler, J. n., Balmanoukian, A. n., George, T. J., Munster, P. n., Berlin, J. D., Gutierrez, M. n., Mita, A. n., Wakelee, H. n., Samakoglu, et al
2019: 1-10

- **First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy** *CANCER MANAGEMENT AND RESEARCH*
Munster, P., Mita, M., Mahipal, A., Nemunaitis, J., Massard, C., Mikkelsen, T., Cruz, C., Paz-Ares, L., Hidalgo, M., Rathkopf, D., Blumenschein, G., Smith, D. C., Eichhorst, et al
2019; 11: 10463-10476
- **Technique development of 3D dynamic CS-EPSI for hyperpolarized C-13 pyruvate MR molecular imaging of human prostate cancer** *MAGNETIC RESONANCE IN MEDICINE*
Chen, H., Larson, P. E. Z., Gordon, J. W., Bok, R. A., Ferrone, M., van Criekinge, M., Carvajal, L., Cao, P., Pauly, J. M., Kerr, A. B., Park, I., Slater, J. B., Nelson, et al
2018; 80 (5): 2062–72
- **Talazoparib and decitabine: a promising combination for BRCA-mutated cancers treatment**
Pacaud, R., Thomas, S., Roche, E., Pawlowska, N., Dhawan, M., Munster, P.
ELSEVIER SCI LTD.2018: E28
- **Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study** *BRITISH JOURNAL OF CANCER*
Munster, P., Krop, I. E., LoRusso, P., Ma, C., Siegel, B. A., Shields, A. F., Molnar, I., Wickham, T. J., Reynolds, J., Campbell, K., Hendriks, B. S., Adiwijaya, B. S., Geretti, et al
2018; 119 (9): 1086-1093
- **Randomized trial of lisinopril or carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving trastuzumab**
Munster, P. N., Krischer, J., Tamura, R., Bello-Matricaria, L., Fink, A., McCaskill-Stevens, W., Guglin, M.
OXFORD UNIV PRESS.2018
- **Effect of JAK/STAT or PI3Kd plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors**
Kirkwood, J. M., Iannotti, N., Cho, D., O'Day, S., Gibney, G., Hodi, F., Munster, P., Hoyle, P., Owens, S., Smith, M., Mettu, N.
AMER ASSOC CANCER RESEARCH.2018
- **A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.**
Hong, D. S., Rasco, D. W., Veeder, M. H., Luke, J. J., Chandler, J., Balmanoukian, A., George, T. J., Munster, P., Berlin, J., Gutierrez, M., Mita, A. C., Wakelee, H. A., Samakoglu, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Phase I-b study of isatuximab plus carfilzomib in relapsed and refractory multiple myeloma (RRMM).**
Chari, A., Richter, J., Shah, N., Wong, S., Jagannath, S., Cho, H. J., Biran, N., Wolf, J., Parekh, S. S., Munster, P. N., Madduri, D., Campana, F., Martin, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.**
Konstantinopoulos, P. A., Waggoner, S. E., Vidal, G. A., Mita, M. M., Fleming, G. F., Holloway, R. W., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., Penson, R. T., Matulonis, U. A., Kim, et al
LIPPINCOTT WILLIAMS & WILKINS.2018
- **Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).**
Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B., Iliopoulos, O., Mier, J., Patel, M. R., Meric-Bernstam, F., DeMichele, A., Voss, M., Harding, J. J., Srinivasan, R., Shapiro, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer**
Kalinsky, K., Harding, J. J., DeMichele, A., Infante, J. R., Gogineni, K., Owonikoko, T. K., Isakoff, S., Iliopoulos, O., Patel, M. R., Munster, P., Telli, M. L., Jenkins, Y., Fiji, et al
AMER ASSOC CANCER RESEARCH.2018

- **Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer** *SCIENTIFIC REPORTS*
Park, J., Thomas, S., Zhong, A. Y., Wolfe, A. R., Krings, G., Terranova-Barberio, M., Pawlowska, N., Benet, L. Z., Munster, P. N.
2018; 8: 92
- **Long-term responders to epigenetic modulators: abexinostat and pazopanib**
Aggarwal, R., Pawlowsk, N., Grabowsky, J., Harb, A., Abri-Lavasani, K., Thomas, S., Munster, P. N.
AMER ASSOC CANCER RESEARCH.2018
- **Pharmacokinetic modeling of differential toxicity to predict alternate dosing schedules**
Dhawan, M., Bartelink, I., Aggarwal, R., Pawlowska, N., Terranova-Barberio, M., Thomas, S., Munster, P.
AMER ASSOC CANCER RESEARCH.2018
- **PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC**
Wong, D., Schneider, J. G., Aljumaily, R., Korn, W. M., Infante, J., Patel, M., Autio, K., Papadopoulos, K., Naing, A., Gabrail, N. Y., Munster, P., Goldman, J., Ratti, et al
OXFORD UNIV PRESS.2017
- **Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors** *CLINICAL CANCER RESEARCH*
Dhawan, M. S., Bartelink, I. H., Aggarwal, R., Leng, J., Zhang, J. Z., Pawlowska, N., Barberio, M., Grabowski, J., Gewitz, A., Chien, A. J., Moasser, M., Kelley, R. K., Maktabi, et al
2017; 23 (21): 6400-6410
- **What advanced cancer patients with limited treatment options know about clinical research: a qualitative study** *SUPPORTIVE CARE IN CANCER*
Garrett, S. B., Koenig, C. J., Trupin, L., Hlubocky, F. J., Daugherty, C. K., Reinert, A., Munster, P., Dohan, D.
2017; 25 (10): 3235-3242
- **Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors** *BREAST CANCER RESEARCH*
Bartelink, I. H., Prideaux, B., Krings, G., Wilmes, L., Lee, P., Bo, P., Hann, B., Coppe, J., Heditsian, D., Swigart-Brown, L., Jones, E. F., Magnitsky, S., Keizer, et al
2017; 19: 107
- **Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update**
Wong, D. J., Schneider, J. G., Aljumaily, R., Korn, M. W., Autio, K., Infante, J. R., Patel, M. R., Papadopoulos, K., Naing, A., Gabrail, N., Munster, P., Goldman, J., Van Vlasselaer, et al
OXFORD UNIV PRESS.2017
- **A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma** *BLOOD*
Martin, T., Baz, R., Benson, D. M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., Vij, R.
2017; 129 (25): 3294-3303
- **Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC** *CANCER IMMUNOLOGY RESEARCH*
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M., Harview, C. L., Taube, J. M., Handley, N., Khurana, N., Nosrati, A., Krummel, et al
2017; 5 (5): 417-424
- **Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay** *CANCER MANAGEMENT AND RESEARCH*
Block, T. S., Murphy, T. I., Munster, P. N., Nguyen, D. P., Lynch, F. J.
2017; 9: 65-71
- **Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)**
Meric-Bernstam, F., Tannir, N., Harding, J., Voss, M., Mier, J., DeMichele, A., Munster, P., Patel, M., Iliopoulos, O., Owonikoko, T., Whiting, S., Orford, K., Bennett, et al
ELSEVIER SCI LTD.2016: S12-S13
- **PHASE I INVESTIGATION OF LENALIDOMIDE PLUS RITUXIMAB AND OUTCOMES OF LENALIDOMIDE MAINTENANCE IN RECURRENT CNS LYMPHOMA**
Rubenstein, J., Fraser, E., Formaker, P., Lee, J., Chen, N., Kock, M., Cheung, W., Killea, P., Choi, K., Wang, X., Munster, P., Damato, B.

OXFORD UNIV PRESS INC.2016: 23-24

- **Interest in Initiating an Early Phase Clinical Trial: Results of a Longitudinal Study of Advanced Cancer Patients.** *Psycho-oncology*
Dunn, L. B., Wiley, J., Garrett, S., Hlubocky, F., Daugherty, C., Trupin, L., Munster, P., Dohan, D.
2016
- **Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)**
Meric-Bernstam, F., Tannir, N. M., Mier, J., DeMichele, A., Telli, M. L., Fan, A. C., Munster, P. N., Carvajal, R. D., Orford, K. W., Bennett, M. K., Iliopoulos, O., Owonikoko, T., Patel, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).**
DeMichele, A., Harding, J. J., Telli, M. L., Munster, P. N., McKay, R., Iliopoulos, O., Orford, K. W., Bennett, M. K., Mier, J., Owonikoko, T., Patel, M. R., Carvajal, R. D., Meric-Bernstam, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma** *ANNALS OF ONCOLOGY*
Thomas, S., Aggarwal, R., Jahan, T., Ryan, C., Troung, T., Cripps, A. M., Raha, P., Thurn, K. T., Chen, S., Grabowsky, J. A., Park, J., Hwang, J., Daud, et al
2016; 27 (5): 947-952
- **First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies** *CLINICAL CANCER RESEARCH*
Munster, P., Aggarwal, R., Hong, D., Schellens, J. H. M., van der Noll, R., Specht, J., Witteveen, P. O., Werner, T. L., Dees, E., Bergsland, E., Agarwal, N., Kleha, J. F., Durante, et al
2016; 22 (8): 1932-1939
- **A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies** *BREAST CANCER RESEARCH AND TREATMENT*
Chien, A., Cockerill, A., Fancourt, C., Schmidt, E., Moasser, M. M., Rugo, H. S., Melisko, M. E., Ko, A. H., Kelley, R., Korn, W., Esserman, L. J., van't Veer, L., Yau, et al
2016; 155 (3): 521-530
- **A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies** *CLINICAL CANCER RESEARCH*
Gupta, S., Argiles, G., Munster, P. N., Hollebecque, A., Dajani, O., Cheng, J. D., Wang, R., Swift, A., Tosolini, A., Piha-Paul, S. A.
2015; 21 (23): 5235-5244
- **Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas** *CANCER DISCOVERY*
Zill, O. A., Greene, C., Sebisano, D., Siew, L., Leng, J., Vu, M., Hendifar, A. E., Wang, Z., Atreya, C. E., Kelley, R. K., Van Loon, K., Ko, A. H., Tempero, et al
2015; 5 (10): 1040-1048
- **Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028**
Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., Van Brummelen, E., Cohen, R., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Yuan, et al
ELSEVIER SCI LTD.2015: S102
- **Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours** *EUROPEAN JOURNAL OF CANCER*
Piha-Paul, S. A., Munster, P. N., Hollebecque, A., Argiles, G., Dajani, O., Cheng, J. D., Wang, R., Swift, A., Tosolini, A., Gupta, S.
2015; 51 (14): 1865-1873
- **A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+metastatic breast cancer**
LoRusso, P., Krop, I., Miller, K., Ma, C., Siegel, B. A., Shields, A. F., Molnar, I., Wickham, T., Reynolds, J., Campbell, K., Hendriks, B., McClure, T., Moyo, et al
AMER ASSOC CANCER RESEARCH.2015
- **More Options for Fertility Preservation for Patients With Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Munster, P. N.

2015; 33 (22): 2413-U7

- **Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer** *BREAST CANCER RESEARCH AND TREATMENT*
 Chien, A., Duralde, E., Hwang, R., Tsung, K., Kao, C., Rugo, H. S., Melisko, M. E., Esserman, L. J., Munster, P. N., Cedars, M., Kerlikowske, K., McCulloch, C. E., Rosen, et al
 2015; 153 (1): 173-181
- **Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.**
 Harding, J. J., Telli, M. L., Munster, P. N., Le, M. H., Molineaux, C., Bennett, M. K., Mittra, E., Burris, H. A., Clark, A., Dunphy, M., Meric-Bernstam, F., Patel, M. R., DeMichele, et al
 AMER SOC CLINICAL ONCOLOGY.2015
- **Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors** *JOURNAL OF CLINICAL ONCOLOGY*
 Daud, A. I., Ashworth, M. T., Strosberg, J., Goldman, J. W., Mendelson, D., Springett, G., Venook, A. P., Loechner, S., Rosen, L. S., Shanahan, F., Parry, D., Shumway, S., Grabowsky, et al
 2015; 33 (9): 1060+
- **Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)**
 Wolin, E., Mita, M., Meyer, T., Bendell, J., Mahipal, A., Nemunaitis, J., Munster, P., Paz-Arez, L., Hull, W., James, A., Trowe, T., Swaminathan, M., Wu, et al
 LIPPINCOTT WILLIAMS & WILKINS.2015: 362
- **Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma**
 Rubenstein, J. L., Formaker, P., Wang, X., Chen, N., Seider, M., Munster, P., Damato, B.
 AMER SOC HEMATOLOGY.2014
- **Phase 1B study of CC-486 (oral azacitidine) in tumors associated with a viral etiology**
 Von Hoff, D. D., Isambert, N., Lopez-Martin, J., Munster, P. N., Rasco, D. W., Bendell, J. C., Schellens, J. M., Tomaro, J., Sarmiento, R., Liu, K., Nguyen, A., Bray, G. L., Hatty, et al
 ELSEVIER SCI LTD.2014: 179
- **A phase I trial of BKM120 combined with vemurafenib in BRAFV600^{E/k} mutant advanced melanoma.**
 Algazi, A., Posch, C., Ortiz-Urda, S., Cockerill, A., Munster, P. N., Daud, A.
 LIPPINCOTT WILLIAMS & WILKINS.2014
- **Phase Ib study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).**
 Munster, P. N., Hamilton, E., Franklin, C., Bhansali, S., Wan, K., Hewes, B., Juric, D.
 LIPPINCOTT WILLIAMS & WILKINS.2014
- **Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer**
 Gupta, S., Munster, P. N., Hollebecque, A., Argues, G., Dajanl, O., Chang, J. D., Swift, A. M., Tosolini, A., Piha-Paul, S.
 LIPPINCOTT WILLIAMS & WILKINS.2014
- **Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.**
 Piha-Paul, S., Munster, P. N., Hollebecque, A., Argiles, G., Dajanl, O., Cheng, J. D., Wang, R., Swift, A. M., Tosolini, A., Gupta, S.
 LIPPINCOTT WILLIAMS & WILKINS.2014
- **Correlation of intratumoral metabolic changes measured with 18F-FDG PET parametric response maps with concentrations of CC-223, a TORC 1/2 kinase inhibitor, in human glioblastoma.**
 Ellingson, B. M., Cloughesy, T., Munster, P. N., Shih, K. C., Bendell, J. C., James, A., Tong, Z., Trowe, T., Chopra, R., Hege, K.
 LIPPINCOTT WILLIAMS & WILKINS.2014
- **Next-generation sequencing of serum microRNA (miRNA) in hepatocellular carcinoma (HCC) patients on targeted therapy.**
 Kelley, R., Chang, A. N., Anguiano, E., Hwang, J., Stoppler, H. J., McWhirter, R. M., Parks, A. L., Hameed, B., Fix, O. K., Wayne, E. M., Nimeiri, H., Munster, P. N., Venook, et al
 LIPPINCOTT WILLIAMS & WILKINS.2014

- **Phase Ib/II study of the PI3K α inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)**
 Razak, A. R. A., Ahn, M., Yen, C., Solomon, B. J., Lee, S., Wang, H., Munster, P. N., L-Van Herpen, C. M., Gilbert, J., Pal, R., Blumenstein, L., Gomez-Carrillo, B., Coughlin, et al
 LIPPINCOTT WILLIAMS & WILKINS.2014
- **SAFETY AND EFFICACY OF MK-8669 (RIDAFOROLIMUS) + MK-2206 (AKT INHIBITOR) IN PATIENTS WITH ADVANCED BREAST CANCER WITH PI3K PATHWAY DEPENDENCE**
 Gupta, S., Munster, P., Hollebecque, A., Argiles, G., Guren, T., Cheng, J., Wang, R., Swift, A., Tosolini, A., Piha-Paul, S.
 OXFORD UNIV PRESS.2014: 25
- **A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with *BRAF* V600E mutation-positive metastatic melanoma** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
 Grippo, J. F., Zhang, W., Heinzmann, D., Yang, K. H., Wong, J., Joe, A. K., Munster, P., Sarapa, N., Daud, A.
 2014; 73 (1): 103-111
- **PET/CT IMAGING OF 64CU-LABELLED HER2 LIPOSOMAL DOXORUBICIN (64CU-MM-302) QUANTIFIES VARIABILITY OF LIPOSOMAL DRUG DELIVERY TO DIVERSE TUMOR LESIONS IN HER2-POSITIVE BREAST CANCER PATIENTS**
 Hendriks, B., Shields, A., Siegel, B. A., Miller, K., Munster, P., Ma, C., Campbell, K., Moyo, V., Wickham, T., LoRusso, P.
 OXFORD UNIV PRESS.2014: 19
- **Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer**
 Munster, P., Krop, I. E., Miller, K., Dhindsa, N., Niyijiza, C., Nielsen, U., Oduyungbo, A., Rajarethinam, A., Marande, M., Campbell, K., Geretti, E., Reynolds, J. G., Hendriks, et al
 AMER ASSOC CANCER RESEARCH.2013
- **Activity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR plus) breast cancer cell lines and patients (pts) with genetically characterized HR plus breast cancer in a Phase I clinical trial.**
 Mita, M. M., Arkenau, H., Bendell, J. C., Munster, P. N., Mahipal, A., Delord, J., Paz-Ares, L. G., Soria, J., Xu, S., Tran, T., Shi, T., Wu, X., Chopra, et al
 AMER ASSOC CANCER RESEARCH.2013
- **Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling** *MOLECULAR CANCER THERAPEUTICS*
 Thurn, K., Thomas, S., Raha, P., Qureshi, I., Munster, P. N.
 2013; 12 (10): 2078-2087
- **Phase Ib study of eribulin (ERB) and cyclophosphamide (CTX) in metastatic breast cancer (MBC).**
 Truong, T., Pelayo, M., Grabowsky, J. A., Melisko, M. E., Magbanua, M., Moasser, M. M., Reinert, A., Hwang, J., Park, J. W., Munster, P. N., Rugo, H. S.
 AMER SOC CLINICAL ONCOLOGY.2013
- **Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.**
 Rugo, H. S., DeLuca, A. N., Heflin, L., Fang, S., Melisko, M. E., Moasser, M. M., Park, J. W., Chien, A., Munster, P. N., Esserman, L., Landau, S. M., Jagust, W. J., Kramer, et al
 AMER SOC CLINICAL ONCOLOGY.2013
- **Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.**
 Heflin, L., Fang, S., DeLuca, A. N., Melisko, M. E., Moasser, M. M., Park, J. W., Chien, A., Munster, P. N., Landau, S. M., Jagust, W. J., Kramer, J. H., Rugo, H. S.
 AMER SOC CLINICAL ONCOLOGY.2013
- **Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-C-13]Pyruvate** *SCIENCE TRANSLATIONAL MEDICINE*
 Nelson, S. J., Kurhanewicz, J., Vigneron, D. B., Larson, P. E., Harzstark, A. L., Ferrone, M., Van Criekinge, M., Chang, J. W., Bok, R., Park, I., Reed, G., Carvajal, L., Small, et al
 2013; 5 (198)
- **Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.** *Annals of oncology : official journal of the European Society for Medical Oncology*
 Kelley, R. K., Nimeiri, H. S., Munster, P. N., Vergo, M. T., Huang, Y., Li, C., Hwang, J., Mulcahy, M. F., Yeh, B. M., Kuhn, P., Luttgen, M. S., Grabowsky, J. A., Stucky-Marshall, et al

2013; 24 (7): 1900-1907

- **Fertility Preservation and Breast Cancer: A Complex Problem** *ONCOLOGY-NEW YORK*
Munster, P. N.
2013; 27 (6): 533-539
- **BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: Two cases.**
Algazi, A., Posch, C., Ortiz-Urda, S., Cockerill, A., Munster, P. N., Daud, A.
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.**
Heflin, L., Fang, S., DeLuca, A. N., Melisko, M. E., Moasser, M. M., Park, J. W., Chien, A., Munster, P. N., Esserman, L., Landau, S. M., Jagust, W. J., Kramer, J. H., Rugo, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.**
Rugo, H. S., DeLuca, A. N., Heflin, L., Fang, S., Melisko, M. E., Moasser, M. M., Park, J. W., Chien, A., Munster, P. N., Esserman, L., Landau, S. M., Jagust, W. J., Kramer, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM)**
Goy, A., Ribrag, V., Varga, A., Witzig, T. E., Ocio, E. M., Paz-Ares, L. G., Mita, M. M., Meyer, T., Munster, P. N., Mahipal, A., Delord, J., Arkenau, H., Gutierrez, et al
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Phase Ib study of safety, tolerability, and efficacy of R1507 a monoclonal antibody to IGF-1R in combination with multiple standard chemotherapy regimens in patients with advanced solid malignancies.**
Mahadevan, D., Sutton, G., Arteta-Bulos, R., Bowden, C. J., Miller, P. J. E., Swart, R., Walker, M. S., Munster, P. N., Dees, E., Marshall, J., Hamid, O., Kurzrock, R.
LIPPINCOTT WILLIAMS & WILKINS.2013
- **Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma** *BLOOD*
Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., Krouwer, H., Hwang, J., Auerback, G., Kadoch, C., Lowell, C., Munster, et al
2013; 121 (5): 745-751
- **A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab** *BREAST CANCER RESEARCH AND TREATMENT*
Lin, N. U., Winer, E. P., Wheatley, D., Carey, L. A., Houston, S., Mendelson, D., Munster, P., Frakes, L., Kelly, S., Garcia, A. A., Cleator, S., Uttenreuther-Fischer, M., Jones, et al
2012; 133 (3): 1057-1065
- **A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.**
Moore, A., Thach-Giao Truong, Thurn, K., Thomas, S., Ryan, C. J., Jahan, T., DuBois, S. G., Chan, J. K., Rugo, H. S., Collisson, E., Raha, P., Chen, S., Reinert, A., et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Phase Ib study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab (bev) with or without paclitaxel.**
Goldman, J., Gordon, M. S., Munster, P. N., Bergsland, E. K., Moore, A., Bai, S., Hegde, P., Fredrickson, J. O., Chang, I., Chandler, G., Funke, R., Rhee, I., Chen, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Munster, P. N., Moore, A. P., Ismail-Khan, R., Cox, C. E., Lacevic, M., Gross-King, M., Xu, P., Carter, W., Minton, S. E.
2012; 30 (5): 533-538
- **Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*

Rubenstein, J. L., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., Krouwer, H., Kadoch, C., Munster, P., Cha, S., Shuman, M. A., Damon, L. E.
AMER SOC HEMATOLOGY.2011: 438-39

- **Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma** *EXPERT OPINION ON INVESTIGATIONAL DRUGS*
Munster, P. N., Daud, A. I.
2011; 20 (11): 1565-1574
- **A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer** *BRITISH JOURNAL OF CANCER*
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., Minton, S. E.
2011; 104 (12): 1828-1835
- **Costello and Cardio-Facio-Cutaneous Syndromes: Moving Toward Clinical Trials in RASopathies** *AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS*
Rauen, K. A., Banerjee, A., Bishop, W., Lauchle, J. O., McCormick, F., McMahon, M., Melese, T., Munster, P. N., Nadaf, S., Packer, R. J., Sebolt-Leopold, J., Viskochil, D. H.
2011; 157C (2): 136-146
- **Inhibition of class I histone deacetylases attenuates anthracycline induced activation of the ATM pathway**
Thurn, K., Thomas, S., Raha, P., Qureshi, I., Munster, P. N.
AMER ASSOC CANCER RESEARCH.2011
- **The HDAC inhibitor PCI-24781 potentiates the anti-tumor activity of tamoxifen in ER-positive breast cancer cells**
Thomas, S., Thurn, K., Raha, P., Munster, P. N.
AMER ASSOC CANCER RESEARCH.2011
- **Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker** *BRITISH JOURNAL OF CANCER*
Munster, P. N., Marchion, D., Thomas, S., Egorin, M., Minton, S., Springett, G., Lee, J., Simon, G., Chiappori, A., Sullivan, D., Daud, A.
2009; 101 (7): 1044-1050
- **Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC** *CLINICAL CANCER RESEARCH*
Munster, P., Marchion, D., Bicaku, E., Lacevic, M., Kim, J., Centeno, B., Daud, A., Neuger, A., Minton, S., Sullivan, D.
2009; 15 (7): 2488-2496
- **Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial**
Daud, A. I., Dawson, J., DeConti, R. C., Bicaku, E., Marchion, D., Bastien, S., Hausheer, F. A., Lush, R., Neuger, A., Sullivan, D. M., Munster, P. N.
AMER ASSOC CANCER RESEARCH.2009: 2479-2487
- **Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma**
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., Heller, R.
AMER SOC CLINICAL ONCOLOGY.2008: 5896-5903
- **Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001. Clinical cancer research : an official journal of the American Association for Cancer Research**
Sausville, E. A.
2001; 7 (8): 2155-8